Recruiting

EchoNet-LVH

Sponsor:

Cedars-Sinai Medical Center

Code:

NCT05139797

Conditions

Cardiac Amyloidosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EchoNet-LVH screening for cardiac amyloidosis

Study Details

Brief summary:

Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine.

Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely/accurately assess common measurements made in clinical practice.

The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis and will prospectively evaluate its accuracy in identifying patients whom would benefit from additional screening for cardiac amyloidosis.

Conditions

Cardiac Amyloidosis

Study ID

NCT05139797

Start date

Nov 18, 2021

Status verified date

Jul, 2026

Completion date

Jun 1, 2027

Anticipated

Primary completion date

Jan 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients who have a high suspicion for cardiac amyloidosis by AI algorithm

Exclusion Criteria:

  • Patients who decline to be seen at specialty clinic
  • Patients who have passed away

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Arms

Artificial Intelligence Screening for Cardiac Amyloidosis

An artificial intelligence algorithm will produce a probability of cardiac amyloidosis that will trigger referral to specialty clinic for further evaluation.

Interventions

EchoNet-LVH screening for cardiac amyloidosis

An AI algorithm identifies LVH, low voltage, and high suspicion for cardiac amyloidosis. The intervention is the suspicion score. Patients with high suspicion score will be referred to specialty clinic for standard of care evaluation, screening, and treatment as determined by physicians.

Primary outcome measure

  • Number of New Diagnoses of Cardiac Amyloidosis Found [ Time Frame: 6 months ]

Central Contacts and Locations

Locations

Cedars-Sinai Medical Centre (Los Angeles)

Recruiting

Los Angeles, California, United States, 90048

Contacts

More Information

Sponsor

Cedars-Sinai Medical Center

Last update posted

Jul 22, 2026

Last verified

Jul, 2026

Keywords

  • Echocardiogram
  • Artificial Intelligence

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Cedars-Sinai Medical Center on 2026-07-22.